• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.03% Nasdaq Up1.29%

    More On 009420.KS

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials


    HanAll Biopharma Co., Ltd. (009420.KS)

    -KSE
    5,250.00 Down 200.00(3.67%) 2:00AM EDT
    Add to Portfolio
    Income StatementGet Income Statement for:
    View: Annual Data | Quarterly DataAll numbers in thousands
    Period EndingDec 31, 2014Dec 31, 2013Dec 31, 2012Dec 31, 2011
    Total Revenue 80,880,000   74,228,000   76,027,000   87,702,000  
    Cost of Revenue40,997,000  42,680,000  40,775,000  44,519,000  
    Gross Profit 39,883,000   31,548,000   35,252,000   43,183,000  
    Operating Expenses
    Research Development -   -   -   -  
    Selling General and Administrative -   -   -   -  
    Non Recurring -   -   -   -  
    Others -   -   -   -  
    Total Operating Expenses80,064,000  87,211,000  79,090,000  94,306,000  
    Operating Income or Loss 815,000   (12,983,000) (3,063,000) (6,604,000)
    Income from Continuing Operations
    Total Other Income/Expenses Net -   -   -   -  
    Earnings Before Interest And Taxes815,000  (12,983,000)(3,063,000)(6,604,000)
    Interest Expense(989,000)(1,374,000)(2,371,000)(3,475,000)
    Income Before Tax -   -   -   -  
    Income Tax Expense(99,000)919,000  (1,050,000)858,000  
    Minority Interest -   -   -   -  
    Net Income From Continuing Ops(12,658,000)(21,499,000)(2,923,000)(14,526,000)
    Non-recurring Events
    Discontinued Operations -   -   -   -  
    Extraordinary Items -   -   -   -  
    Effect Of Accounting Changes -   -   -   -  
    Other Items -   -   -   -  
    Net Income (12,658,000) (21,499,000) (2,923,000) (14,526,000)
    Preferred Stock And Other Adjustments -   -   -   -  
    Net Income Applicable To Common Shares -   -   -   -  

    Currency in KRW.